PD-L1 monoantial Tecentriq and VEGF monoantial Avastin: Approved to treat the most common liver cancer patients in China

Roche announced that the National Drug Administration (NMPA) has approved PD-L1 monoantigen Tecentriq (atezolizumab) combined anti-vascular endodermal growth factor (VEGF) monoantigen avastin (beva monoantigen) for patients with irreversible, non-excisive hepatocellular carcinoma (HCC).
: "Nearly half of the world's hepatocellular carcinoma patients are in China, and this approval marks a significant advance in the treatment of hepatocellular carcinoma in China," said Levi Garraway, Roche's chief medical officer.
Professor Qin Shuxuan, Chairman of the Expert Committee on Liver Cancer of the Chinese Society of Clinical Oncology (CSCO), said: "Primary liver cancer is the fourth most common malignant tumor in China, and most patients in the middle and late stages are no longer able to choose surgery or other topical therapies when they are diagnosed, so new treatments are urgently needed."
IMbrave150 study showed that tecentriq and Avastin combined can significantly improve patient prognostics.
the portfolio has now been approved in China, providing new options for liver cancer patients in China.
" liver cancer is one of the most common cancers in China, diagnosing nearly 400,000 cases each year and causing about 368,000 deaths, equivalent to more than 1,000 deaths a day.
average five-year survival rate for liver cancer patients in China is only about 15%.
The approval was based on the results of the Phase III IMbrave150 study, which showed that Tecentriq and Avastin reduced the risk of death (overall survival rate, OS) by 56 percent and the risk of disease deterioration or death (no progression, PFS) by 40 percent compared to Sorafini.
and Tecentriq and Avastin have good tolerance and are easy to control.
IMbrave150 Global Study found that the Tecentriq and Avastin combinations reduced the risk of death (OS) by 42 per cent and the risk of disease deterioration or death (PFS) by 41 per cent compared to Solafini.
results were published in the New England Journal of Medicine on May 14, 2020.
photo source: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020。